Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05973773 · ClinicalTrials.gov registry record · Phase 3
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
A Phase 3 study of Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, sponsored by Taiho Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 285
- Enrollment target
- 20
- Study locations
NCT05973773: Active Phase 3 study of Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, sponsored by Taiho Oncology.
NCT05973773 is a Phase 3 study of Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation that is active but no longer recruiting, run by Taiho Oncology. The registered enrollment target is 285 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05973773, a Phase 3 study of Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, is active but no longer recruiting, sponsored by Taiho Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 285 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Conditions Studied
Interventions
- DRUG TAS6417
Study Locations (20)
Nevada
- Comprehensive Cancer Centers of Nevada - Henderson - Henderson
- Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson - Henderson
- Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie - Henderson
- Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II - Las Vegas
- Comprehensive Cancer Centers of Nevada - Southwest - Las Vegas
- Comprehensive Cancer Centers of Nevada - Central Valley - Twain - Las Vegas
- Comprehensive Cancer Centers of Nevada - Northwest - Las Vegas
Rio Grande do Sul
- Hospital Mãe de Deus - Centro Integrado de Oncologia - Porto Alegre
- Hospital São Lucas da PUCRS - Porto Alegre
Ohio
- Gabrail Cancer and Research Center - Canton
Texas
- University of Texas MD Anderson Cancer Center - Houston
Flemish Brabant
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg - Leuven
Oost-Vlaaderen
- Algemeen Ziekenhuis Maria Middelares - Ghent
West Flanders
- Algemeen Ziekenhuis Delta - Campus Menen - Menen
West-Vlaanderen
- Algemeen Ziekenhuis Delta - Campus Rumbeke - Rosières
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2027-05-27 |
| Phase | Phase 3 |
What the registry record for NCT05973773 still lists
NCT05973773 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation appearing as the primary indexed condition, and to 1 intervention - of which TAS6417 is the first listed.
NCT05973773 names 20 study sites across 13 states, led by Nevada, Rio Grande do Sul, Ohio.
Frequently Asked Questions
What is clinical trial NCT05973773 about?
NCT05973773 is a clinical study titled "REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)". The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
What is the current status of trial NCT05973773?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 285 participants. The study started on 2023-12-18. Estimated completion is 2027-05-27.
What conditions does trial NCT05973773 study?
This clinical trial studies the following conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation.
What interventions are being tested in trial NCT05973773?
The interventions under investigation include: TAS6417 (DRUG).
Who is sponsoring clinical trial NCT05973773?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05973773 being conducted?
This trial has 20 study locations across Nevada, Ohio, Texas, Flemish Brabant, Oost-Vlaaderen. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05973773's enrollment target sits among peer trials
285 1186th of 2000 higher than 812 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI